LEO Pharma

We have Michael Kier Olson, Director, Head of Digital Innovation and Automation at KPMG.

And we have Parag Naitani, Head of Statistical Programming over at Leo Pharma.

We're all here today to discuss unlocking business value through purposeful data and AI innovation.

So before we get into the topic, I wanted to, you know, work our way around the room with some introductions.

everyone.

My name is Parag.

And I work in Leo Pharma.

I'm heading up the statistical programming group at Leo Pharma.

The deal puts Biomarin in closer competition with larger companies including AstraZeneca in rare bone disease.

Number 12, Leo Pharma signed a deal with Tanabe worth up to $435 million to continue the trend of companies looking externally for pipeline assets rather than relying exclusively on internal R&D.

Number 13, Sanofi's KeyMap bad falters.

Not every deal works out.

None.

Meanwhile, LEO Pharma paid up to four hundred and thirty-five million dollars for a rare disease pill already sitting at the FDA, and a new study says gray market retatrutide is nowhere near trial numbers.

Let’s take the week apart.

Welcome to the Pharma Close-Out Week in Review for Sunday, August twenty-third.

Set that next to the other big move of the week and something clicks.

Capital went toward assets where the uncertainty has already been spent.

LEO Pharma acquired worldwide rights to dersimelagen from Tanabe Pharma, up to four hundred and thirty-five million dollars in upfront and near-term milestones, plus downstream milestones and tiered royalties.

Oral once-daily MC1R agonist for erythropoietic protoporphyria and X-linked protoporphyria.